On November 6, Philip Morris fell 3.22% in Regular Trading, trading at $198.97 per share, with turnover of $127 million.
The move coincided with a fresh market interpretation that heavy investment behind ZYN is likely to weigh on near-term US profitability, overshadowing the company’s recent quarterly beat.
Recent commentary indicated ZYN-related spending could lift fourth-quarter selling, general and administrative expenses by about 10% sequentially, implying US operating companies income may be around break-even or slightly negative. That concern followed the company’s latest quarterly report, where adjusted EPS of $2.36 and revenue of $11.44 billion both topped expectations, but full-year adjusted EPS guidance had already been reduced to $8.11 to $8.26 from the earlier $8.35 to $8.50 range, reinforcing the market’s focus on short-term margin pressure even as longer-term smoke-free growth remains intact.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments